logo

Drug Development

Share SHARE

Elililly-090717.jpg Eli Lilly and Co. (LLY) said Thursday that it plans to cut about 3,500 positions globally, as part of a streamlining plan. It expects to incur charges of about $1.2 billion pre-tax or $0.80 per share after-tax. It expects annualized savings of about $500 million that will begin to be realized in 2018.

Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application or sBLA and granted Priority Review for Gazyva or obinutuzumab in combination with chemotherapy followed by Gazyva alone for people with...

Mylan N.V. (MYL) said that its subsidiaries, Mylan Inc. and Mylan Specialty L.P., have signed an agreement with the U.S. Department of Justice and two relators finalizing the Medicaid drug rebate settlement that the Company announced on October 7, 2016 for $465 million. The settlement resolved...

Merck (MRK) said that it has accepted the external Data Monitoring Committee recommendation to pause new enrollment on KEYNOTE-183 and KEYNOTE-185, two studies exploring KEYTRUDA treatment in combination with other therapies in the blood cancer multiple myeloma. The company noted that the pause is...

Follow RTT